Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed, Christina L Roark, Lizamarie Bachier-Rodriguez, Lawrence E. Morris, Jr., H. Kent Holland, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 7738–7739.

https://doi.org/10.1182/blood-2022-164804

Published: 2022

Journal Articles

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Melhem Solh, Scott R. Solomon, Xu Zhang, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, H. Kent Holland, Asad Bashey

Blood (2022) 140 (Supplement 1): 4745–4746.

https://doi.org/10.1182/blood-2022-164773

Published: 2022

Journal Articles

Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Asad Bashey, Xu Zhang, Melhem Solh, H. Kent Holland, Lawrence E. Morris, Jr., Lizamarie Bachier-Rodriguez, Scott R. Solomon

Blood (2022) 140 (Supplement 1): 11007–11008.

https://doi.org/10.1182/blood-2022-163574

Published: 2022

Journal Articles

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

Rebecca Farley, Eva Karam, Xu Zhang, Asad Bashey, H. Kent Holland, Lawrence E. Morris, Jr., Scott R. Solomon, Melhem Solh

Blood (2022) 140 (Supplement 1): 11694–11695.

https://doi.org/10.1182/blood-2022-167938

Published: 2022

Journal Articles

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Asad Bashey, Lawrence E. Morris, Jr., H. Kent Holland, Melhem Solh

Blood (2022) 140 (Supplement 1): 10618–10619.

https://doi.org/10.1182/blood-2022-158803

Published: 2022

Journal Articles

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Jr., Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 7647–7648.

https://doi.org/10.1182/blood-2022-162788

Published: 2022

Journal Articles

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Asad Bashey, Xu Zhang, Scott R. Solomon, Lizamarie Bachier-Rodriguez, H. Kent Holland, Lawrence E. Morris, Jr., Melhem Solh

Blood (2022) 140 (Supplement 1): 7568–7569.

https://doi.org/10.1182/blood-2022-156852

Published: 2022

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Scott R. Solomon, Lizamarie Bachier-Rodriguez, Xu Zhang, Michael T. Aubrey, Christina L. Roark, Lawrence E. Morris, Jr., H. Kent Holland, Asad Bashey, Melhem Solh

Blood (2022) 140 (Supplement 1): 4861–4862.

https://doi.org/10.1182/blood-2022-158759

Published: 2022

Journal Articles

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, Melhem Solh, Lawrence E. Morris, Jr., H. Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey

Blood (2022) 140 (Supplement 1): 1188–1189.

https://doi.org/10.1182/blood-2022-158797

Published: 2022

Journal Articles

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use

Asad Bashey, Xu Zhang, H. Kent Holland, Lawrence E Morris, Jr., Scott R. Solomon, Melhem Solh

Blood (2021) 138 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2021-151747

Published: 2021

Journal Articles

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Blood (2016) 128 (8): 1050–1058.

https://doi.org/10.1182/blood-2015-08-664706

Published: 2016

Journal Articles

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Scott R. Solomon, MD, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD

Blood (2012) 120 (21): 4468.

https://doi.org/10.1182/blood.V120.21.4468.4468

Published: 2012

Journal Articles

Assessing Fatigue and Distress in Caregivers of Hematopoetic Stem Cell Transplant Patients.

Dawn Speckhart, Ph.D., Scott R. Solomon, MD, Asad Bashey, MD, PhD, Lawrence E. Morris, Jr., MD, Shondolyn Richburg, H. Kent Holland, MD

Blood (2012) 120 (21): 3169.

https://doi.org/10.1182/blood.V120.21.3169.3169

Published: 2012

Journal Articles

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Amaani Hussain, Connie A. Sizemore, PharmD, Xu Zhang, PhD, Melissa Sanacore, PharmD, Stacey Brown, B.A., Karen Manion, RN, Lawrence E. Morris, Jr., MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2012) 120 (21): 3030.

https://doi.org/10.1182/blood.V120.21.3030.3030

Published: 2012

Journal Articles

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, MD, Jonathan M. Gerber, MD, Amanda Blackford, Mark Litzow, MD, Matthew C. Foster, MD, Lawrence E. Morris, Jr., MD, Ivana Gojo, MD, Jeffrey E. Lancet, MD, Prithviraj Bose, MD, Raoul Tibes, MD, Stephen A. Strickland, MD, MSCI, Jacqueline M Greer, RN, Michelle Drye, Kevin Meads, Austin Doyle, MD, Richard F Little, MD, MPH, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 47.

https://doi.org/10.1182/blood.V120.21.47.47

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus

Real-World Data on the Incidence and Management of Blinatumomab Toxicities in Adult Patients with Minimal Residual Disease and Relapsed or Refractory Acute Lymphoblastic Leukemia

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide

Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

Assessing Fatigue and Distress in Caregivers of Hematopoetic Stem Cell Transplant Patients.

Lineage–Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center.

Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only